Search results - 33 results
Development of a multiplex-based immunoassay for the characterization of diphtheria, tetanus and acellular pertussis antigens in human combined DTaP vaccines.
Vaccines Diphtheria-Tetanus-Pertussis Vaccine Humans Hydrogen Peroxide Immunization, Secondary Immunoassay Reproducibility of Results Tetanus Whooping Cough Abstract: Routine batch quality testing before ...
SARS-CoV-2 infection prevention and control measures in Belgian schools between December 2020 and June 2021 and their association with seroprevalence: a cross-sectional analysis of a prospective cohort study
secondary schools in Belgium between December 2020 and June 2021. The implementation of IPC measures in schools was assessed using a questionnaire. Schools were classified according to their compliance with ...
SARS-CoV-2 seroprevalence and determinants for salivary seropositivity among pupils and school staff: a prospective cohort study
also in October and December 2021 for primary pupils. We recruited 885 primary and 569 secondary pupils and 799 staff in 84 schools. Cumulative seroprevalence (95% CI) among primary pupils increased from ...
Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up.
IgM and IgG against the receptor binding domain of SARS-CoV-2 and to complete an online questionnaire at each of maximum eight testing time points. PRIMARY AND SECONDARY OUTCOME MEASURES: The ...
Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients.
risk of developing severe disease. This is challenging, however, since effective mRNA vaccination requires the successful cooperation of several components of the innate and adaptive immune systems, both ...
Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer.
Viral Biomarkers BNT162 Vaccine COVID-19 Vaccines Humans Immunity, Humoral Immunization Schedule Immunization, Secondary Immunogenicity, Vaccine Neoplasms Prospective Studies Risk Factors Time Factors ...
Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium during 1 year of the COVID-19 epidemic: prospective cohort study protocol.
and complete an online questionnaire. The primary outcomes are the prevalence and incidence of antibodies against SARS-CoV-2 in PHCP s during a 12-month follow-up period. Secondary outcomes include the ...
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the DAWn-Plasma trial.
Therapy COVID-19 Female Global Burden of Disease Hospitalization Humans Immunization, Passive Male mortality Respiration, Artificial SAFETY SARS-CoV-2 Standard of Care Treatment Outcome Abstract: ...
Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.
Count Coinfection Double-Blind Method Female Healthy Volunteers HIV Infections Hiv-1 Humans Immunity, Active Immunization, Secondary Immunoglobulin G Injections, Intradermal Male middle aged Mycobacterium ...
DNA vaccines against tuberculosis.
Antigens, Bacterial BCG Vaccine Humans Immunization, Secondary Mycobacterium tuberculosis T-Lymphocytes, Cytotoxic Tuberculosis, Pulmonary Vaccination Vaccines, DNA Abstract: INTRODUCTION: Tuberculosis (TB) ...